NImmune Biopharma

IBD-focused biotech (private)

Privately held: no public share price · United States

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
omilancorNo recent activity
Phase 2
LANCL2Small molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease
NIM-1324No recent activity
Phase 1
LANCL2Small molecule
Inflammatory Bowel DiseaseSystemic Lupus Erythematosus
Ulcerative Colitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.